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Chemical Product Research & Development
Eli Lilly and Company
• Corporate Headquarters: Indianapolis, Indiana
• Founded in 1876 • More than 40,000 employees worldwide
• In the last decade, we have introduced important drugs for the treatment of cancer, 
osteoporosis, ADHD, diabetes, cardiovascular complications,  and sepsis
• Approximately 8,300 employees are engaged in R&D
Development of a Medicine
Formulation R&D GMP Manufacture,
non-GMP DevelopnmentAPI + Excipients
API
Process R&D Route Selected & Optimized,
GMP Manufacture, non-GMP
Development
API
Discovery Candidate Selection
Initial Route
20 mg Prozac
 Single ELN Used across these areas
Current ELN Summary
• > 600,000 experiments created with ELN Software 
& Record  integrity demonstrated for 6 years.
• ~1100  Users Presently Use Single Platform ELN
- Discovery (400+)
- Development (200)
- Formulations (100)
- Analytical Sciences (50)
- Contract R&D (300)
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ELN System Overview 
Critical Discussions with Legal
• Initially, we had perceived concerns about 
Legal’s comfort with moving away from hard-
copy signatures. 
• This concern ended up being totally 
misplaced! 
• Bottom line:  proceed with e-signatures.  
Critical Discussions with Quality
• Initial discussions considered allowing the use of 
electronic lab notebooks, but still maintaining a 
hard-copy archive.  
• Based on concerns about data integrity between 
hard and e-copies, we proceeded with an electronic 
archive only: 100% paperless since 2004.  
• Although we are not currently using the system for 
GMP content, it is fully GMP validated.  GMP 
validation also made our Legal colleagues more 
comfortable from a systems-robustness 
perspective.  
• GMP and GLP content are coming…
Lab Hardware Recommendation
– Wireless keyboard and 
mouse or keyboard w/ 
integrated pointing device. 
– Flat panel monitor mounted 
on a swing-arm keeps bench 
space clear.
– Small form factor PC stored 
on top shelf of bench out of 
potential “splash zone”
– All scientists have been 
provided option of 
additional Computer 
System for their lab area.
– Post Deployment: KVM 
switches have become 
popular options
Avoidance of Customizations
• Our early constraint was to avoid customization at 
almost any cost, rather to work with the provider to 
get the capability in place in the core product, even 
if that meant we had to wait for it.  
• Customizations can be expensive and have issues 
with version upgrades.
• Lilly Customizations to date:  
– Notebook Management System
– Sample Registration 
– Green Chemistry (some enhancements)
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• Our early constraint was to avoid customization at 
almost any cost, rather to work with the provider to 
get the capability in place in the core product, even 
if that meant we had to wait for it.  
• Customizations can be expensive and have issues 
with version upgrades.
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– Sample Registration 
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Take home message: Caveat emptor,  beware of
vendors bearing customizations
The 12 Principles of Green Chemistry*
1. Prevent waste
2. Design safer chemicals and products
3.  Design less hazardous chemical syntheses
4.  Use renewable feed-stocks 
5.  Use catalysts, not stoichiometric reagents 
6.  Avoid chemical derivatives
7.  Maximize atom economy 
8.  Use safer solvents and reaction conditions
9.  Increase energy efficiency
10.  Design chemicals and products to degrade after use
11.  Analyze in real time to prevent pollution
12.  Minimize the potential for accidents
* http://www.epa.gov/greenchemistry/pubs/principles.html
Eli Lilly and Companies “e-Factor”
• *Lilly’s e-factor:   total mass of all raw materials, including water 
that are used to produce each kg of active pharmaceutical ingredient 
(API) beginning from routinely available commercial starting 
materials.
• e-factor guidelines: 
- Route Selection Completion < 300 kg/kg API (Phase 1)
- Process Definition Completion < 200 kg/kg API (Phase 2)
- Process Optimization Completion < 100 kg/kg API (Phase 3)
• Regular e-factor assessments occur at project milestones
• Lilly’s e-factor now takes into account third party starting material 
process…….encourages responsible outsourcing.
* Based on Sheldon’s E-factor, see Sheldon, R. D., Chem. Ind. (London) 1992, 903.
Environmental Definitions
• TRI: Toxic Release inventory;  Database of potentially 
hazardous chemical maintained by EPA.
• PBT: Persistent Bio-accumulate and Toxic; Database of 
toxic, non biodgradable chemicals which are highly 
hazardous (e.g. Lead, Dioxin, PCB’s, etc.)
• Yellow List: Lilly Proprietary List of Hazardous 
Chemcials – Similar to TRI.
• Solvent Tier: Lilly Environmental Ranking of Solvents 
• PMI: Process Mass intensity = e-factor (kg total  
material per kg of API)
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Environmental Definitions
• TRI: Toxic Release inventory;  Database of potentially hazardous 
chemical maintained by EPA .
• PBT: Persistent Bio-accumulate and Toxic; Database of toxic, non 
biodgradable chemicals which are highly hazardous (e.g. Lead, 
Dioxin, PCB’s, etc.)
• Yellow List: Lilly Proprietary List of Hazardous Chemcials – Similar 
to TRI.
• Solvent Tier: Lilly Environmental Ranking of Solvents 
• PMI: Process Mass intensity = e-factor (Kg total  material per kg of 
API)
• Custom Report Developed within ELN to Report TRI, PBT, 
yellow list chemicals, solvent tier and PBT for components of 
an individual reaction and  an entire process.
• Calculation of step PMI and PMI for entire process.
• Successfully Deployed to all Users in Dec. 08.
Solvent Tier Classifications
• Tier 1 =  water, CO2  (That’s it!)
• Tier 2 =  ethyl acetate, ethanol, heptane, etc.
• Tier 3 =  DMSO, methanol, THF, etc.
• Tier 4 =  MTBE, Dioxane, CH2Cl2, etc.
• Tier 5 =  Diethyl  ether, hexane, CS2, etc 
• Tier 6 =  Benzene, CCl4 (Banned Solvents)
• Justification Required for  Use of a Tier 4 solvent 
or Lower in Lilly Manufacturing
• Solvent Classification reviewed annually.
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2. CSA (1 eq) / EtOAc
90 %
Replaced With: 
 Cycle time Reduce to 2-3 days per lot.
 Quaternization Minimized due to sequential  
freebase (piperidone = slow)
 Step PMI = 15
 MT quantities produced by several third parties
 Bis Michael Addition = 1 week w. 
~ 3 week cycle time per lot.
 Piperidone Prepared as DCM soln
with low purity.
 Step PMI = 100
 Methodology general and applied to the synthesis of other pharmaceutically  active cpds: 
A) *Kopach, M. E.; Kobierski, M.E.; Faul, M. M. J. Org. Chem. 2003, 68 (14) 5739. B) Boini, S.   
*Moder, K. P.; Vaid, R. K.; Kopach M. E.; Kobierski, M. E. Org. Process Res. Dev.; 2006; 10(6), 1205.
Original Route :
2-Benzenesulfonyl Pyridine Synthesis
N S
O
ON SN Br
1.  PhSH (2 eq.),
TEA (2 eq.), Reflux
2. DCM / NaOH
1. MMPP (1.0 eq),
    DMF, reflux
2. Water
65% yield
Original Procedure:
• 2 equivalents thiophenol- refuxing temps;
• Hazards Assoc with MMPP addition (5 min refluxing DMF);
• Large quantities of waste generated from MMPP, oxidation can stall at sulfoxide.
• PMI  = 75 kg/kg product 
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1.  PhSH (1 eq.),
K2CO3 (1.2 eq.), 110oC
85-90% yield
DMF, 8 hours
2.  Cool to 23oC; Filter
3.  HOAC (4 equiv.)
4. 8-13% NaOCl
5. Water
• 2 equivalents thiophenol- refuxing temps;
• Hazards Assoc with MMPP addition (5 min refluxing DMF);
• Large quantities of waste generated from MMPP, oxidation can stall at sulfoxide.
• PMI  = 75 kg/kg product 
Fully Developed:
• Tandem SNAr / oxidation Sequence to produce 2-phenyl sulfonyl pyridines*
• Atom economy:  Use of 2-chloro pyridine
• Green Chemical Oxidation: “swimming pool chlorine” replaces MMPP
• PMI = 25/kg/kg product 
• Cost Savings / New Process = $100 / Kg  
* Trankle, W. G. and Kopach, M. E. Org. Process Res. Dev. 2007 11, 5, 913. 
   
Planned Amounts Actual 
Amounts 
Materials 
Step 1 
   Solvent Tier 
PBT Listed 
Chemicals 
TRI Listed 
Chemicals    
Class Name Lot Number g moles    g moles 
Reactants  
 Pyridine, 2-Chloro- 1420KB 14.2 0.13    14.4 0.13 
 benzenethiol [LR] 16709AB 15.0 0.13    15.1 0.13 
Chemicals  
 K2CO3 072K01381 22.1 0.16    22.0 0.16 
 DMF  01946EC 179.6 2.46 3  X 151.2 2.08 
 10.6 % NaOCl A019794301 280 0.40    240 0.34 
 Water  30 1.67 1   130 7.22 
 Potassium 
Hydroxide  27.1 0.10    42.1 0.15 
 Acetic Acid  7.9 0.13 2   10.5 0.17 
Products  
 2-Phenyl Sulfonyl 
Pyridine XXX 28.96 0.13    24.7 0.11 
Step PMI      19.9         25.3   
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LILLY ELN Green Sheet
ELN Material Import Interface
ELN Global E-factor Report 
(7 Step Route)
Global E-Factor Report
Background
Investigator: M. Kopach
Project Number: -]
Project Name: -
Experiment Name: Global e-factor/ PMI Test
Date Modified: Thursday, February 07, 2008
Description: Multistep Application
Summary
Planned
PMI
Actual
PMI
Yellow
List
PBT
Chemical
s
TRI
Chemicals
Tier 1
Solvent
Tier 2
Solvent
Tier 3
Solvent
Tier 4
Solvent
Tier 5
Solvent
Step 1 23.93 25.45 0 0 1 1 1 1 0 0
Step 2 22.82 23.89 0 0 1 1 1 1 0 0
Step 3 23.42 23.42 2 1 1 1 1 1 0 0
Step 4 18.25 22.68 0 0 0 1 1 0 0 0
Step 5 22.58 27.46 1 0 1 0 2 2 0 0
Step 6 18.72 19.43 0 0 2 1 1 1 0 0
Step 7 15.61 16.54 0 0 0 0 2 0 0 0
Total Reaction 145.84 152.46 3 1 6 5 9 6 0 0
E-Factor Workflow
• Chemical lists created and stored within ELN for 
TRI, Yellow list and PBT chemicals.  
• Solvent lists created and stored within ELN 
which contain tier data.
• User must import materials from Green 
Chemistry Repository Individually 
• Custom report Available – can export to Word, 
PDF or Print
• All materials used in the process must be 
entered in materials table!
Proposed Future Green Chemistry Reports
Single Experiment Report:
Step % yield Theor. PMI 
(kg/kg API)
Actual. PMI 
(kg/kg API)
Step PMI
% Contrib
Aqueous
PMI
Aqueous
% Contrib
Solvent
PMI
Solvent
% Contrib
1
2
3
Total
MultiStep Synthesis Report:
Step % Yield Theor. 
Step PMI 
Actual  
Step PMI 
Aqueous  
PMI 
Aqueous 
% Contrib 
Solvent 
PMI 
Solvent 
% Contrib 
1        
 
Additional  Future Directions
• Ability to import multiple chemicals in one action with 
current tool 
• Longer-term Integration with all chemical import tools
• Retrofit Green chemistry tool with experiments 
generated in prior ELN versions
• Revisit concept of i-ELN.  Have software auto search the 
chemical, patent literature, internal databases then 
suggest green chemical alternative reagents and 
procedures for an individual reaction.
• Have system suggest optimization of  an individual 
reaction based on literature and internal data.
• Lifecycle Reporting
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E-factor Improvements: Process Dev. Lifecycle
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Archiving Strategy
Conversion of experimental data to an alternate 
format for safekeeping – pdf chosen due to track 
record.
100 experiments constitutes a complete 
notebook……..corporate standard.
Each experiment has archive report available in 
pdf.
Embedded documents / files (.doc, xls, jpeg, etc.) 
are contained in the archive report.
Embedded objects not printable will be listed in 
archive report (e.g. sound or movie files).
Archiving on demand, per legal request.
Archiving live since  06.
IT Reverts Exp. for correction, needs 
to be re-countersigned
Read/ Write for AuthorReverted8
Countersigner returns experiment to 
author for correction
Read/ Write for AuthorReturned7
Read OnlyCountersigned6
30 Day Countersigning Extension 
Granted
Read/ Write for AuthorCountersigned- Active5
Request for 30 Day Experiment 
completion Extension
Read Only for authorRequest Countersign
Active
4
Experiment Ready for 
Countersignature
Read  Only for authorSigned3
Stage requested by scientistsRead / Write for AuthorComplete- Waiting for
Data
2
Experiment in WorkRead / Write for AuthorIn process1
Purpose Document StatusTransition
Experiment is Complete
Most Common Experiment Workflow
Workflow Example
